[ad_1]
A drug for the treatment of acute myocardial infarction, developed by the Center for Genetic Engineering and Biotechnology (CIGB), will be available in Cuba next year, announced today the newspaper Granma
. CIGB-500, the product, consisting of six amino acids, will extend the quality and lifespan of people with this disease, considered one of the most serious diseases of ischemic heart disease, stresses office.
cytoprotection during hepatic or cardiac ischemia and episodes of reperfusion occurred when the relevant times were used during the surgery, explained the Director of Promotion and National Distribution of CIGB, José Brito, in the newspaper
and preclinical. In 2008, a Phase I clinical trial was completed in healthy volunteers and since November 2013, Phase II has begun in affected patients, said Brito.
Following the studies conducted, it was concluded that CIGB-500 is incompatible with the most commonly used drugs for the treatment of this disease, said Yunia Delgado, a specialist in the Center's communication group.
With the development of this synthetic peptide, it should meet the national demand and join the system. National Health and Export, Advanced Delgado
According to the report on biomedical projects in the Business Portfolio of the ICOLD, this project is the first drug used for the treatment of this disease
. decrease the extent of infarction, protect the body's epithelial organs from damage caused by ischemia-reperfusion events, treat liver injury and control and reduce the progression of liver fibrosis .
According to the Statistical Yearbook of Public Health, acute myocardial infarction is the third leading cause of death from heart disease in Cuba, responsible for the deaths of seven thousand 177 people in 2017.
Cardiac reperfusion is a medical procedure that can save a person's life after a heart attack.
(With information from Prensa Latina)
Author: Radio Angulo Email: This email address is being protected from spambots.
Other articles by this author
[ad_2]
Source link
